<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02549989</url>
  </required_header>
  <id_info>
    <org_study_id>15-079</org_study_id>
    <nct_id>NCT02549989</nct_id>
  </id_info>
  <brief_title>Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer</brief_title>
  <official_title>Single-Arm, Open-Label, Phase II Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness of LY3023414 in treating the&#xD;
      participants type of cancer and to determine the types and severity of side effects caused by&#xD;
      treatment with LY3023414.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clinical benefit rate (CBR)</measure>
    <time_frame>≥12 weeks from the start of treatment</time_frame>
    <description>defined as the percentage of patients with complete response (CR) + partial response (PR) + stable disease (SD) ≥12 weeks from the start of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>overall response rate</measure>
    <time_frame>1 year</time_frame>
    <description>determined by RECIST 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival (PFS)</measure>
    <time_frame>1 year</time_frame>
    <description>defined as the duration of time from start of treatment to time of recurrence, progression, or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Endometrial Cancer</condition>
  <condition>Recurrent Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>LY3023414</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is an MSKCC investigator-initiated, single-center, non-randomized, open-label, phase II study to evaluate the activity of LY3023414 dosed at the RP2D of 200 mg orally twice daily in patients with recurrent or persistent endometrial cancer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3023414</intervention_name>
    <description>Enrolled patients will take LY3023414 200 mg orally twice a day. Each cycle will be 21 days in duration. Patients will receive study treatment until disease progression, intolerable toxicity, elective withdrawal from the study, study completion, or study termination</description>
    <arm_group_label>LY3023414</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have recurrent or persistent endometrial carcinoma Patients with the&#xD;
             following histologic epithelial cell types are eligible: endometrioid adenocarcinoma,&#xD;
             serous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed&#xD;
             epithelial carcinoma, adenocarcinoma not otherwise specified (N.O.S.), mucinous&#xD;
             adenocarcinoma, squamous cell carcinoma, transitional cell carcinoma, and&#xD;
             carcinosarcoma.&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Patients must have had at least one but no more than four prior chemotherapeutic&#xD;
             regimens for management of endometrial carcinoma (including neo-adjuvant and/or&#xD;
             adjuvant chemotherapy). Initial treatment may include chemotherapy, chemotherapy and&#xD;
             radiation therapy, and/or consolidation/maintenance therapy. Chemotherapy administered&#xD;
             in conjunction with primary radiation as a radio-sensitizer WILL be counted as a&#xD;
             systemic chemotherapy regimen.&#xD;
&#xD;
          -  Patients tumors must have known PI3K pathway activation defined as EITHER of the&#xD;
             following on a CLIA-approved molecular diagnostics test:&#xD;
&#xD;
          -  Genomic alteration resulting in loss of PTEN function including a) whole or partial&#xD;
             gene deletion, frame shift mutations, or non-sense mutations. Missense mutations in&#xD;
             PTEN will not be considered qualifying.&#xD;
&#xD;
          -  A previously characterized activating mutation in any component of the pathway&#xD;
             including: PIK3CA, AKT1, PIK3R1, PIK3R2, mTOR&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          -  Resolution of adverse effects of recent surgery, radiotherapy, or chemotherapy to&#xD;
             Grade ≤1 prior to first study treatment (with the exception of alopecia or&#xD;
             neuropathy).&#xD;
&#xD;
          -  Patients must have measurable disease. Measurable disease is defined by RECIST&#xD;
             (version 1.1). Measurable disease is defined as at least one lesion that can be&#xD;
             accurately measured in at least one dimension (longest diameter to be recorded). Each&#xD;
             lesion must be ≥ 10 mm when measured by CT, MRI or caliper measurement by clinical&#xD;
             exam; or ≥ 20 mm when measured by chest x-ray. Lymph nodes must be ≥ 15 mm in short&#xD;
             axis when measured by CT or MRI.&#xD;
&#xD;
          -  No active infection requiring antibiotics (with the exception of uncomplicated urinary&#xD;
             tract infection).&#xD;
&#xD;
          -  Any other prior therapy directed at the malignant tumor, including immunologic agents&#xD;
             and radiotherapy, must be discontinued at least 2 weeks prior to first study&#xD;
             treatment.&#xD;
&#xD;
          -  Adequate hematologic defined by the following laboratory results obtained within 14&#xD;
             days prior to first study treatment:&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) ≥1500/10^9dL&#xD;
&#xD;
          -  Platelet count ≥ 100,000/10^9dL&#xD;
&#xD;
          -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
          -  Adequate hepatic function defined by the following laboratory results obtained within&#xD;
             14 days prior to first study treatment:&#xD;
&#xD;
          -  Total bilirubin≤1.5x the upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT ≤ 3.0x ULN (unless the patient has Gilbert's Syndrome, in which case AST&#xD;
             and ALT ≤ 5.0x ULN is permitted&#xD;
&#xD;
          -  Albumin ≥ 3.5 g/dL&#xD;
&#xD;
          -  Adequate renal function defined by the following laboratory results obtained within 14&#xD;
             days prior to first study treatment:&#xD;
&#xD;
          -  Serum creatinine≤1.5x ULN OR creatinine clearance ≥50 mL/min on the basis of the&#xD;
             Cockcroft-Gault glomerular filtration rate estimation&#xD;
&#xD;
          -  For all patients (regardless of known diabetes) the following is required at&#xD;
             screening: Fasting blood glucose ≤ 135 mg/dL (7.49 mmol/L) and HbA1c ≤7.0%&#xD;
&#xD;
          -  For patients of childbearing potential, agreement to use two effective forms of&#xD;
             contraception (e.g., surgical sterilization, a reliable barrier method, birth control&#xD;
             pills, or contraceptive hormone implants) and to continue its use for the duration of&#xD;
             the study and for 30 days after the last LY3023414 dose.&#xD;
&#xD;
          -  Patients must have been enrolled, or agree to consent to the companion genomic&#xD;
             profiling study MSKCC IRB# 12-245.&#xD;
&#xD;
          -  Willingness to sign written informed consent to this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with known concurrent activating RAS/RAF mutation or loss of function&#xD;
             mutation or deletion in NF1 of NF2 resulting in MAP kinase pathway activation.&#xD;
             Patients are not required to be evaluated for these alterations if not already&#xD;
             performed.&#xD;
&#xD;
          -  Patients with diabetes requiring insulin or requiring more than one non-insulin&#xD;
             hypoglycemia agents.&#xD;
&#xD;
          -  Patients previously treated with an mTOR, AKT, or PI3K inhibitor (including but not&#xD;
             limited to GDC-0941, GDC-0980, BEZ235, BKM120, LY294002, PIK-75, TGX-221, XL147,&#xD;
             XL765, SF1126, PX-866, D-87503, D-106669, GSK615, CAL101, everolimus, temsirolimus,&#xD;
             and ridaforolimus). For agents not listed, the Study PI or Co-PI will make a&#xD;
             determination.&#xD;
&#xD;
          -  History of myocardial infarction or unstable angina within 6 months prior to first&#xD;
             study treatment.&#xD;
&#xD;
          -  New York Heart Association Class II or greater congestive heart failure.&#xD;
&#xD;
          -  Patients with a QTcF interval of &gt;450 msec on screening electrocardiogram (ECG) Note:&#xD;
             If &gt;450 msec on the first ECG, 2 additional ECGs can be ordered same day and then the&#xD;
             average may be used to determine eligibility.&#xD;
&#xD;
          -  History of malabsorption syndrome or other condition that would interfere with enteral&#xD;
             absorption.&#xD;
&#xD;
          -  Inability or unwillingness to swallow pills&#xD;
&#xD;
          -  Clinically significant history of liver disease, including cirrhosis and current&#xD;
             alcohol abuse.&#xD;
&#xD;
          -  Active hepatitis B or hepatitis C infection. Patients with previously resolved&#xD;
             hepatitis B infection are eligible. Presence of positive test results for hepatitis B&#xD;
             infection who have resolved the infection (defined by being positive for HB surface&#xD;
             antibody (anti-HBs) and polymerase chain reaction (PCR) assay is negative for HBV DNA)&#xD;
             are eligible. Patients positive for HCV antibody are eligible only if testing for HCV&#xD;
             RNA is negative.&#xD;
&#xD;
          -  Known HIV infection.&#xD;
&#xD;
          -  Need for current chronic corticosteroid therapy (≥ 10 mg of prednisone per day or an&#xD;
             equivalent dose of other anti-inflammatory corticosteroids)&#xD;
&#xD;
          -  Pregnancy, lactation, or breastfeeding&#xD;
&#xD;
          -  Current severe, uncontrolled systemic disease (e.g., clinically significant&#xD;
             cardiovascular, pulmonary, or metabolic disease)&#xD;
&#xD;
          -  Major surgical procedure or significant traumatic injury within 28 days prior to Day 1&#xD;
             or anticipation of the need for major surgery during the course of study treatment.&#xD;
&#xD;
          -  Known untreated or active central nervous system (CNS) metastases (progressing or&#xD;
             requiring anticonvulsants or corticosteroids for symptomatic control). Patients with a&#xD;
             history of treated CNS metastases are eligible, provided that they meet all of the&#xD;
             following criteria:&#xD;
&#xD;
          -  Presence of measurable disease outside the CNS&#xD;
&#xD;
          -  No radiographic evidence of worsening upon the completion of CNS-directed therapy and&#xD;
             no evidence of interim progression between the completion of CNS-directed therapy and&#xD;
             the screening radiographic study&#xD;
&#xD;
          -  No history of intracranial hemorrhage or spinal cord hemorrhage&#xD;
&#xD;
          -  No ongoing requirement for dexamethasone as therapy for CNS disease (anticonvulsants&#xD;
             at a stable dose are allowed)&#xD;
&#xD;
          -  Absence of leptomeningeal disease&#xD;
&#xD;
          -  Inability to comply with study and follow-up procedures.&#xD;
&#xD;
          -  Any other disease, metabolic dysfunction, physical examination finding, or clinical&#xD;
             laboratory finding that, in the investigator's opinion, gives reasonable suspicion of&#xD;
             a disease or condition that contraindicates the use of an investigational drug or that&#xD;
             may affect the interpretation of the results or render the patient at high risk from&#xD;
             treatment complications.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vicky Makker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering at Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 11, 2015</study_first_submitted>
  <study_first_submitted_qc>September 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2015</study_first_posted>
  <last_update_submitted>June 16, 2021</last_update_submitted>
  <last_update_submitted_qc>June 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LY3023414</keyword>
  <keyword>15-079</keyword>
  <keyword>Persistent Endometrial Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

